Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.
EP. 1: Defining Germline Sequencing and Incidental Germline Findings
Mark Robson, MD, and a panel of experts discuss key terminology and definitions related to tumor and germline sequencing.
EP. 2: Tumor-Normal Matched Sequencing and Platforms Utilized for Tumor Profiling
Mark Robson, MD, reviews data from a recent abstract on incidental germline findings detected by tumor-normal matched sequencing and the panelists share which platforms they utilize for tumor profiling.
EP. 3: Experience with Interpreting Somatic Reports
A panel of experts share their experiences with interpreting information on somatic reports and provide recommendations for verifying results.
EP. 4: Identification of Patients for Germline Testing
The panel of experts provide insight on how they identify patients for germline testing.
EP. 5: Role of ctDNA in Germline Testing
Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss the evolving role of circulating tumor DNA (ctDNA) in germline testing.
EP. 6: Operational Processes and Challenges
Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.